
B2
CAS No. 115687-05-3
B2( CPNQ | Linazolamide intermediate B impurity 2 | 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline )
Catalog No. M27605 CAS No. 115687-05-3
B2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 140 | In Stock |
![]() ![]() |
10MG | 222 | In Stock |
![]() ![]() |
25MG | 376 | In Stock |
![]() ![]() |
50MG | 536 | In Stock |
![]() ![]() |
100MG | 777 | In Stock |
![]() ![]() |
500MG | 1548 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameB2
-
NoteResearch use only, not for human use.
-
Brief DescriptionB2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
-
DescriptionB2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
-
In Vitro——
-
In Vivo——
-
SynonymsCPNQ | Linazolamide intermediate B impurity 2 | 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
-
PathwayOthers
-
TargetOther Targets
-
RecptorGABAB
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number115687-05-3
-
Formula Weight396.83
-
Molecular FormulaC20H17ClN4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (126.00 mM)
-
SMILES[O-][N+](=O)c1ccc(N2CCN(CC2)C(=O)c2ccc(Cl)cc2)c2cccnc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Q Gillani, et al. CGP 35348, GABA B receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. Biomed Res Int.?2014;2014:295215.
molnova catalog



related products
-
MethADP
MethADP (Adenosine 5'-(α,β-methylene)diphosphate) is a specific CD73 inhibitor that inhibits the enzyme ecto-5′-nucleotidase (ecto), which has been used in the study of neurological and cardiovascular diseases.
-
Poricoic acid A
Poricoic acid A is a natural product with antitumor activity. It also enhances melatonin inhibition of AKI-to-CKD transition by regulating the Gas6/AxlNFκB/Nrf2 axis.
-
10-O-trans-p-coumaro...
10-O-trans-p-coumaroylscandoside,posseses Antioxidant activities and vasodilator effects.